ArticleBMC women's health2025
Analysis of global ovarian cancer disease burden and its changing trend from 1990 to 2021.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Optimized SPE-HPLC-FLD Method for the Simultaneous Determination of Olaparib, Propranolol, and Furosemide in Human Urine.Biomedical chromatography : BMC · 2026Article
- Synthesis and application of quercetin hybrids as potential anticancer agents in the treatment of ovarian cancer.Scientific reports · 2026Article
- Burden, Regional Trends and Risk Factors of Breast, Cervical, Uterine, and Ovarian Cancers in Sub-Saharan Africa, 1990-2023: The Global Burden of Disease 2023.International journal of environmental research and public health · 2026Article
- Analysis of ovarian cancer burden among reproductive-aged women and its association with the socio-demographic index from 1990 to 2021.World journal of surgical oncology · 2026Article
- Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older.JAMA network open · 2026Article
- Bidirectional Association between Atrial Fibrillation and Ovarian Cancer: Evidence from the UK Biobank and Mendelian Randomization.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Article
- Temporal Trends in Mortality of Female Cancers Among Women and the Impact of COVID-19 in Low- and Middle-Income Countries, 1990-2023: An Age-Period-Cohort Analysis from the Global Burden of Disease Study 2023.International journal of women's health · 2026Article
- Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.Frontiers in oncology · 2026Article
- Women with suspected diagnosis of ovarian cancer in Ghana: how much do we know about them?Frontiers in oncology · 2026Article
- Nanotechnology-Assisted Co-Delivery of Immunotherapeutic Agents for Targeting Ovarian Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Global burden of ovarian cancer attributable to high BMI, 1990-2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study.Journal of ovarian research · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
Abstract
backgroundResearch on the burden of disease for ovarian cancer (OC) remains notably limited at present. The objective of this study is to conduct a comprehensive analysis of the Global Burden of Disease (GBD) study, spanning the period from 1990 to 2021, in order to elucidate the incidence and burden of OC. This will thereby inform targeted policies and strategies related to prevention, screening, and treatment.
methodsThe incidence and disability-adjusted life years (DALYs) of OC were analyzed based on age group and sociodemographic index (SDI). The estimated annual percentage change (EAPC) was employed to evaluate trends in OC over the period from 1990 to 2021.
resultsGlobally, the incidence of OC has risen significantly from 159,096 cases in 1990 to 298,876 cases in 2021. The corresponding global age-standardised incidence rates (ASIR) of OC demonstrated a significant increase from 1990 to 2021 (EAPC = 0.06), while the global age-standardised DALY rates of OC indicated a decrease (EAPC=-0.38). Central Europe presented with both the highest ASIR and DALY rates (10.8 and 205.22 per 100,000 respectively). At the regional and country level, Andean Latin America exhibited the most rapid increases in ASIR and DALYs (EAPC = 2.12 and 4.90 respectively), with the largest increases being observed in Ecuador (EAPC = 6.64 and 6.39 respectively). These data suggest that the global standardised incidence rate of OC peaks between the ages of 70 and 74.
conclusionGlobally, the burden of ASIR due to OC has risen steadily from 1990 to 2021. This increase has been particularly pronounced in countries with low and medium SDI and in individuals aged between 70 and 74 years. The regions that currently bear the brunt of this disease include Central and Eastern Europe, Andean Latin America, and Sub-Saharan Africa. Notably, there is an observable shift in disease burden towards regions with lower socioeconomic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.